

FOR PRESCRIBING VETERINARIANS

Frequently asked questions about Adequan® Canine (polysulfated glycosaminoglycan)

ABOUT ADEQUAN® CANINE

What is Adequan® Canine?

Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) for dogs. It is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

Adequan® Canine is a prescription formulation PSGAG. It is a DMOAD which inhibits cartilage loss in a dog's joints.

Are there age or breed restrictions for Adequan® Canine?

No age or breed restrictions; use in pregnant, breeding or lactating animals has not been evaluated.

How is Adequan® Canine packaged?

Adequan® Canine is a solution that is colorless to slightly yellow; 100 mg/mL in a 5 mL preserved multiple-dose vial, packaged 2 vials per box.

What is the dosage and administration?

2 mg/lb (.02 mL/lb or 1 mL/50 lb) by intramuscular injection only, twice weekly for up to 4 weeks (maximum of 8 injections).

How fast does Adequan® Canine work?

It begins to work in the joint within 2 hours and stays in the joint for approximately 3 days.¹

What is the pharmacology of Adequan® Canine?

- Low molecular weight allows the distribution of PSGAG from the bloodstream to the synovial fluid.
- Distribution from the synovial fluid to the cartilage takes place by diffusion.
- In the articular cartilage, the drug is deposited into the cartilage matrix.
- PSGAG reaches synovial fluid within 2 hours of injection.¹
- Detectable levels are maintained in synovial fluid and articular cartilage for up to 72 hours.¹
- The specific mechanism of action of Adequan® Canine in canine joints is not known.

MODE OF ACTION & EFFICACY

What is the Mechanism of Action for Adequan® Canine?

The specific mechanism of action of Adequan® Canine in joints is not known. *In vitro* research suggests PSGAG:

- Inhibits certain catabolic enzymes which have increased activity in inflamed joints.
- Enhances the activity of anabolic enzymes.
- Stimulates the synthesis of protein, collagen, proteoglycans and hyaluronic acid by chondrocytes and synoviocytes.
- Potentiates hyaluronic acid synthesis by synovial membrane cells.
- In the articular cartilage the drug is deposited into cartilage matrix and may help shield against further degradation.

What is the proof of efficacy for Adequan® Canine?

Efficacy demonstrated in two studies, radiolabeled and clinical field trials.

- A study was conducted of the distribution of radiolabeled PSGAG into canine serum, synovial fluid and articular cartilage following a single IM injection of 2 mg/lb. Synovial fluid protein (an indicator of synovial inflammation) was significantly reduced in the shoulder joint.¹
- Field trial: Dogs (n=51) with radiographically detectable degenerative joint disease in one or two limbs were administered IM injections twice weekly for 4 weeks (total of 8 injections). Dogs treated with Adequan® Canine had statistically significant improvement in range of motion and orthopedic scores compared with placebo-treated control dogs.¹

For additional Pharmacology and Efficacy information, see the Full Prescribing Label on page 4.

HOW TO USE: PROTOCOL

Can I give Adequan® Canine to a dog already taking an NSAID?

American Regent Animal Health (ARAH) has not completed any trials or studies identifying the combination use of NSAIDs and Adequan® Canine (polysulfated glycosaminoglycan or PSGAG).

What is the treatment protocol for a new patient starting with Adequan® Canine?

The approved label dose of Adequan® Canine is 2 mg/lb body weight (.02 mL/lb or 1 mL/50 lb), by intramuscular injection only, twice weekly for up to 4 weeks (maximum of 8 injections).

Do not exceed the recommended dose or therapeutic regimen. Do not mix Adequan® Canine with other drugs or solvents. Be sure to practice aseptic techniques in withdrawing each dose to decrease the possibility of post-injection bacterial infections. Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe. Use only sterile needles and use each needle only once.

What is the treatment protocol after the first 8 injections?

The approved label dose of Adequan® Canine is 2 mg/lb body weight (.02 mL/lb or 1 mL per 50 lb), by intramuscular injection only, twice weekly for up to 4 weeks (maximum of 8 injections). We have no further studies or technical data supporting a use protocol beyond the approved label dosing.

Do I have to keep Adequan® Canine refrigerated?

No, Adequan® Canine needs to be stored at 68° to 77° F (20° to 25° C) with excursions permitted to 59° to 86° F (15° to 30° C). You need to avoid prolonged exposure to temperatures greater or equal to 104° F (40° C).

Can I give Adequan® Canine subcutaneously instead of by intramuscular injection?

Adequan® Canine is approved only for intramuscular injection.

Is Adequan® Canine in a multiple-use vial?

Yes, Adequan® Canine contains a preservative, which allows for multiple punctures of an individual vial. A product vial must be used within 28 days of first puncture and is limited to a maximum puncture of 10 times. Please properly dispose of spent needles in accordance with all federal, state and local environmental laws.

HOW DOES ADEQUAN® CANINE COMPARE?

What is the difference between FDA-approved prescription Adequan® Canine and other over-the-counter products?

There are many supplements and over-the-counter products making similar claims to Adequan® Canine. However, these products are only supported by statements and do not have the structured and qualified product testing and trials Adequan® Canine completed to obtain FDA-approval.

Adequan® Canine is the only FDA-approved disease-modifying osteoarthritis drug for use in dogs and is recommended for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

SAFETY INFORMATION

Are there any Contraindications?

Do not use in dogs showing a hypersensitivity to PSGAG. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.

Any Precautions?

The safe use of Adequan® Canine used in breeding, pregnant, or lactating dogs has not been evaluated. Use with caution in dogs with renal or hepatic impairment.

What is the current ISI (Important Safety Information) statement?

Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please [Click Here](#) for Full Prescribing Information.

For additional Protocol and Safety information, see the Full Prescribing Label on page 4.

ABOUT AMERICAN REGENT ANIMAL HEALTH

The manufacturer of Adequan® Canine

American Regent Animal Health (ARAH), a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products.

As the manufacturer of Adequan® (polysulfated glycosaminoglycan), the company is positioned as a leader in joint health care for dogs and horses. American Regent Animal Health is committed to maximizing our ability to serve you and your patients.

Where can I find out more about American Regent Animal Health?

For more information, visit ARAnimalHealth.com

HOW TO PURCHASE

How can I order Adequan® Canine?

Your Adequan® Canine needs can be serviced through a wide network of authorized veterinary distributors. Please go to the website, adequancanine.com or call ARAH at 800-458-0163.

Can veterinarians or pet owners purchase Adequan® Canine directly from American Regent Animal Health?

We have established a wide network of distributors that make purchase easy. If you want to buy directly from ARAH, we can have our National Key Accounts Manager reach out to you to discuss options. And since this is a prescription-only product, pet owners must purchase through a licensed, practicing veterinarian.

How do I return expired product?

Short-dated or expired Adequan® Canine product should be returned to the distributor that originally supplied the product, per the established return policies. Contact your distributor or American Regent Animal Health at 800-458-0163.

Do I have an ARAH sales representative I can call?

Yes, you can contact ARAH direct at 800-458-0163 if you would like to connect with your ARAH sales representative or contact your local distributor if you need to place an order.

Which distributors currently carry Adequan® Canine?

- Patterson Vet — 800-225-7911
- MWI — 800-824-3703
- Henry Schein Vet — 855-724-3461
- Midwest Vet — 800-643-9378
- Penn Vet — 800-233-0210
- Victor Medical — 800-888-8908

FOR MORE INFORMATION

Where can I get marketing and in-clinic material?

You can coordinate obtaining marketing and promotional material through your local Adequan® Canine sales representative or by contacting American Regent Animal Health directly. To learn more, please visit adequancanine.com or call ARAH at 800-458-0163.

Who can I call with questions about Adequan® Canine?

To speak to a customer service representative, please call 800-458-0163 Monday-Friday, 8 a.m. to 6 p.m. ET or email cs@americanregent.com. For technical questions, call Medical Affairs at 888-354-4855 Monday-Friday, 9 a.m. to 5 p.m. ET. To report an adverse event, call 800-734-9236 or email pv@americanregent.com.

Is there a website?

Yes, you can learn more at adequancanine.com.

